{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:28:09Z","timestamp":1790551689000,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"crossref","award":["101015736"],"award-info":[{"award-number":["101015736"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"crossref","award":["PHRC-20-0351"],"award-info":[{"award-number":["PHRC-20-0351"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"crossref","award":["R20117HD"],"award-info":[{"award-number":["R20117HD"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fonds Erasme-COVID-Universit\u00e9 Libre de Bruxelles"},{"DOI":"10.13039\/501100019353","name":"Belgian Health Care Knowledge Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100019353","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Austrian Group Medical Tumor"},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Portugal Ministry of Health"},{"name":"Portugal Agency for Clinical Research and Biomedical Innovation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The antiviral efficacy of remdesivir in COVID-19 hospitalized patients remains controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To estimate the effect of remdesivir in blocking viral replication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed nasopharyngeal normalized viral loads from 665 hospitalized patients included in the DisCoVeRy trial (NCT 04315948; EudraCT 2020-000936-23), randomized to either standard of care (SoC) or SoC + remdesivir. We used a mathematical model to reconstruct viral kinetic profiles and estimate the antiviral efficacy of remdesivir in blocking viral replication. Additional analyses were conducted stratified on time of treatment initiation (\u22647 or &amp;gt;7\u2005days since symptom onset) or viral load at randomization (&amp;lt; or \u22653.5 log10 copies\/104 cells).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In our model, remdesivir reduced viral production by infected cells by 2-fold on average (95% CI: 1.5\u20133.2-fold). Model-based simulations predict that remdesivir reduced time to viral clearance by 0.7\u2005days compared with SoC, with large inter-individual variabilities (IQR: 0.0\u20131.3\u2005days). Remdesivir had a larger impact in patients with high viral load at randomization, reducing viral production by 5-fold on average (95% CI: 2.8\u201325-fold) and the median time to viral clearance by 2.4\u2005days (IQR: 0.9\u20134.5\u2005days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Remdesivir halved viral production, leading to a median reduction of 0.7\u2005days in the time to viral clearance compared with SoC. The efficacy was larger in patients with high viral load at randomization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkac048","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T15:13:31Z","timestamp":1644419611000},"page":"1404-1412","source":"Crossref","is-referenced-by-count":46,"title":["Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-6220","authenticated-orcid":false,"given":"Guillaume","family":"Lingas","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, INSERM, F-75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"N\u00e9ant","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, INSERM, F-75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Gaymard","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, D\u00e9partement de Virologie, Institut des Agents Infectieux, Centre National de R\u00e9f\u00e9rence des virus des infections respiratoires France Sud, F-69004, Lyon, France"},{"name":"Universit\u00e9 de Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Universit\u00e9 Claude Bernard Lyon 1, F-69372, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drifa","family":"Belhadi","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, INSERM, F-75018 Paris, France"},{"name":"AP-HP, H\u00f4pital Bichat, D\u00e9partement d\u2019\u00c9pid\u00e9miologie, Biostatistique et Recherche Clinique, F-75018, Paris, France"},{"name":"CIC-EC 1425, INSERM, F-75018, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-537X","authenticated-orcid":false,"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, INSERM, F-75018 Paris, France"},{"name":"AP-HP, H\u00f4pital Bichat Claude Bernard, Laboratoire de Pharmacologie-toxicologie, F-75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Hites","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire de Bruxelles-H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles, Clinique des maladies infectieuses, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Staub","sequence":"additional","affiliation":[{"name":"Centre hospitalier de Luxembourg, Service des maladies infectieuses, L-1210 Luxembourg, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, 5020 Salzburg, Austria"},{"name":"Cancer Cluster Salzburg, 5020, Salzburg, Austria"},{"name":"AGMT, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose-Artur","family":"Paiva","sequence":"additional","affiliation":[{"name":"Centro Hospitalar S\u00e3o Jo\u00e3o, Emergency and Intensive Care Department, Porto, Portugal"},{"name":"Universidade do Porto, Faculty of Medicine, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Poissy","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lille, Inserm U1285, CHU Lille, P\u00f4le de r\u00e9animation, CNRS, UMR 8576 - UGSF - Unit\u00e9 de Glycobiologie Structurale et Fonctionnelle, F-59000, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1166-1958","authenticated-orcid":false,"given":"Nathan","family":"Peiffer-Smadja","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, INSERM, F-75018 Paris, France"},{"name":"AP-HP, H\u00f4pital Bichat, Service de Maladies Infectieuses et Tropicales, F-75018 Paris, France"},{"name":"National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Costagliola","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, Institut Pierre-Louis d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, F-75013, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, INSERM, F-75018 Paris, France"},{"name":"AP-HP, H\u00f4pital Bichat, Service de Maladies Infectieuses et Tropicales, F-75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Wallet","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Intensive R\u00e9animation anesth\u00e9sie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Benite, France"},{"name":"Universit\u00e9 Claude Bernard Lyon 1, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, F-69372, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0892-2187","authenticated-orcid":false,"given":"Amandine","family":"Gagneux-Brunon","sequence":"additional","affiliation":[{"name":"CHU de Saint-Etienne, Service d\u2019Infectiologie, F-42055 Saint-Etienne, France"},{"name":"Universit\u00e9 Jean Monnet, Universit\u00e9 Claude Bernard Lyon 1, GIMAP, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, F-42023 Saint-Etienne, France"},{"name":"CIC 1408, INSERM, F-42055 Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Mentr\u00e9","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, INSERM, F-75018 Paris, France"},{"name":"AP-HP, H\u00f4pital Bichat, D\u00e9partement d\u2019\u00c9pid\u00e9miologie, Biostatistique et Recherche Clinique, F-75018, Paris, France"},{"name":"CIC-EC 1425, INSERM, F-75018, Paris, France"},{"name":"AP-HP, H\u00f4pital Bichat, Unit\u00e9 de Recherche Clinique, F-75018, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Ader","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Claude Bernard Lyon 1, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, F-69372, Lyon, France"},{"name":"Hospices Civils de Lyon, D\u00e9partement des maladies infectieuses et tropicales, F-69004, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Burdet","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, INSERM, F-75018 Paris, France"},{"name":"AP-HP, H\u00f4pital Bichat, D\u00e9partement d\u2019\u00c9pid\u00e9miologie, Biostatistique et Recherche Clinique, F-75018, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-5482","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie","family":"Guedj","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, INSERM, F-75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maude","family":"Bouscambert-Duchamp","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, D\u00e9partement de Virologie, Institut des Agents Infectieux, Centre National de R\u00e9f\u00e9rence des virus des infections respiratoires France Sud, F-69004, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"2022042812395578800_dkac048-B1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"2022042812395578800_dkac048-B2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"2022042812395578800_dkac048-B3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2021","journal-title":"N Engl J Med"},{"key":"2022042812395578800_dkac048-B4","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2\u2005M pro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"2022042812395578800_dkac048-B5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","author":"Group","year":"2021","journal-title":"medRxiv"},{"key":"2022042812395578800_dkac048-B6","article-title":"Therapeutic Management. COVID-19 Treatment Guidelines","author":"NIH"},{"key":"2022042812395578800_dkac048-B7","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"2022042812395578800_dkac048-B8","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 \u2014 Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"2022042812395578800_dkac048-B9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for Covid-19 \u2014 Interim WHO Solidarity Trial Results","volume":"384","author":"WHO Solidarity Trial Consortium","year":"2021","journal-title":"N Engl J Med"},{"key":"2022042812395578800_dkac048-B10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.7326\/M21-0653","article-title":"Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19","volume":"174","author":"Barratt-Due","year":"2021","journal-title":"Ann Intern Med"},{"key":"2022042812395578800_dkac048-B11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"key":"2022042812395578800_dkac048-B12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"2022042812395578800_dkac048-B13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"2022042812395578800_dkac048-B14","doi-asserted-by":"crossref","DOI":"10.1101\/2020.06.21.163550","article-title":"Mathematical modeling explains differential SARS CoV-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques","volume-title":"bioRxiv","author":"Goyal","year":"2020"},{"key":"2022042812395578800_dkac048-B15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022042812395578800_dkac048-B16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/psp4.12543","article-title":"Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load","volume":"9","author":"Gon\u00e7alves","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2022042812395578800_dkac048-B17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.2223","article-title":"Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies","volume":"110","author":"Gastine","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2022042812395578800_dkac048-B18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2017962118","article-title":"Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort","volume":"118","author":"N\u00e9ant","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022042812395578800_dkac048-B19","doi-asserted-by":"crossref","first-page":"e041437","DOI":"10.1136\/bmjopen-2020-041437","article-title":"Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults","volume":"10","author":"Ader","year":"2020","journal-title":"BMJ Open"},{"key":"2022042812395578800_dkac048-B20","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/ca448e7c-fbbc-43e9-9981-108c9bfa8bce","article-title":"Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: A randomized placebo-controlled trial","volume":"7","author":"Duval","year":"2010","journal-title":"PLoS Med"},{"key":"2022042812395578800_dkac048-B21","doi-asserted-by":"crossref","DOI":"10.1101\/2020.09.25.20201772","article-title":"Kinetics of SARS-CoV-2 infection in the human upper and lower respiratory tracts and their relationship with infectiousness","volume-title":"medRxiv","author":"Ke","year":"2020"},{"key":"2022042812395578800_dkac048-B22","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111477118","article-title":"In vivo kinetics of SARS-CoV-2 infection and its relationship with a person\u2019s infectiousness","volume":"118","author":"Ke","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022042812395578800_dkac048-B23","article-title":"Summary on compassionate use, Remdesivir, Gilead","author":"EMA"},{"key":"2022042812395578800_dkac048-B24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1208\/s12248-020-0426-7","article-title":"Model Averaging in Viral Dynamic Models","volume":"22","author":"Gon\u00e7alves","year":"2020","journal-title":"AAPS J"},{"key":"2022042812395578800_dkac048-B25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10928-017-9550-0","article-title":"Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection","volume":"44","author":"Aoki","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2022042812395578800_dkac048-B26","doi-asserted-by":"crossref","first-page":"14977","DOI":"10.1038\/s41598-021-93828-y","article-title":"Clinical and laboratory characteristics of symptomatic healthcare workers with suspected COVID-19: a prospective cohort study","volume":"11","author":"Bal","year":"2021","journal-title":"Sci Rep"},{"key":"2022042812395578800_dkac048-B27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/infdis\/jiab283","article-title":"Virological characterization of critically Ill patients with COVID-19 in the United Kingdom: Interactions of viral load, antibody status, and B.1.1.7 infection","volume":"224","author":"Ratcliff","year":"2021","journal-title":"J Infect Dis"},{"key":"2022042812395578800_dkac048-B28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1008752","article-title":"Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action","volume":"17","author":"Czuppon","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"2022042812395578800_dkac048-B29","first-page":"33","article-title":"Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients","author":"Dougan","year":"2021","journal-title":"Top Antivir Med"},{"key":"2022042812395578800_dkac048-B30","article-title":"Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice","author":"Martinez","year":"2021","journal-title":"bioRxiv"},{"key":"2022042812395578800_dkac048-B31","doi-asserted-by":"crossref","DOI":"10.1101\/2022.01.17.476685","article-title":"Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant","volume-title":"bioRxiv","author":"Rosales","year":"2022"},{"key":"2022042812395578800_dkac048-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/science.abi5273","article-title":"Estimating infectiousness throughout SARS-CoV-2 infection course","volume":"373","author":"Jones","year":"2021","journal-title":"Science"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/5\/1404\/43480506\/dkac048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/5\/1404\/43480506\/dkac048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T08:41:27Z","timestamp":1651135287000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/5\/1404\/6540540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3,2]]},"published-print":{"date-parts":[[2022,4,27]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac048","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.10.19.21265209","asserted-by":"object"}]},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,3,2]]}}}